Table 1.
(A) Patient characteristics and comorbidities, (B) prior history of urothelial carcinoma of the bladder, (C) tumour characteristics of the PC specimen, (D) surgical characteristics, and (E) hospitalization course.
| Overall cohort (n = 27) | |
|---|---|
| (A) | |
| Epidemiological characteristics | |
| Age (years) | 66.0 (56.0–76.0) |
| Sex m/f (%) | 19/8 (70.4/29.6) |
| Plasma creatinine (mg/dl) | 0.85 (0.74–1.12) |
| Haemoglobin (g/dl) | 13.8 (12.8–15.2) |
| Charlson comorbidity index | 3 (0–5) |
| Charlson comorbidity grade (age adjusted) (%) | |
| Median grade | 3 (2–4) |
| Grade 1 (no comorbidity) = o pts | 2 (7.4) |
| Grade 2 (slight-moderate comorbidity) = 1–2 pts | 8 (29.6) |
| Grade 3 (intermediate-severe comorbidity) = 3–4 pts | 5 (18.5) |
| Grade 4 (very severe comorbidity) ≥5 pts | 12 (44.4) |
| Adult Comorbidity Evaluation-27 (ACE-27) (%) | |
| None | 6 (22.2) |
| Mild | 5 (18.5) |
| Moderate | 3 (11.1) |
| Severe | 13 (48.1) |
| Karnofsky index (%) | |
| 100% | 16 (59.3) |
| 90% | 2 (7.4) |
| 80% | 6 (22.2) |
| 70% | 2 (7.4) |
| 60% | 1 (3.7) |
| 0–50% | 0 (0.0) |
| ECOG performance status (%) | |
| 1 | 18 (66.7) |
| 2 | 8 (29.6) |
| 3 | 1 (3.7) |
| 4–5 | 0 (0.0) |
| (B) | |
| Prior history of urothelial carcinoma of the bladder | |
| Primary pathological tumour stage (UICC 2009) (%) | |
| pTa | 2 (7.4) |
| pT1 | 4 (14.8) |
| pT2 | 21 (77.8) |
| pT2a | 4 (14.8) |
| pT2X | 17 (63.0) |
| Presence of concomitant Carcinoma in situ (CIS) (%) | 4 (14.8) |
| Primary tumour grading (WHO 1973) (%) | |
| Grade 1 | 2 (7.4) |
| Grade 2 | 4 (14.8) |
| Grade 3 | 21 (77.8) |
| Primary tumour grading (WHO 2004) (%) | |
| High-grade papillary urothelial carcinoma | 25 (92.6) |
| Low-grade papillary urothelial carcinoma | 2 (7.4) |
| Tumour stage at time of indicaton for PC (UICC 2009) (%) | |
| p/cT2 | 27 (100.0%) |
| pT2a | 4 (14.8) |
| pT2X | 23 (85.2) |
| Presence of concomitant Carcinoma in situ (CIS) at time of indication for PC (%) | 0 (0.0) |
| Tumour grading at time of indication for PC (WHO 1973) (%) | |
| Grade 1 | 0 (0.0) |
| Grade 2 | 3 (11.1) |
| Grade 3 | 24 (88.9) |
| Tumour grading at time of indication for PC (WHO 2004) (%) | |
| High-grade papillary urothelial carcinoma | 27 (100.0) |
| Neoadjuvant therapy prior PC (%) | 5 (18.5) |
| BCG intravesical instillation | 5 (18.5) |
| Mitomycin intravesical instillation | 0 (0.0) |
| Chemotherapy | 0 (0.0) |
| Radiation | 0 (0.0) |
| Time to progression from non-MIBC to MIBC (pT2) prior PC (months) | 9.2 (1.8–40.7) |
| (C) | |
| Tumour characteristics of the PC specimen | |
| Histology of the PC specimen (%) | |
| Pure urothelial carcinoma | 18 (66.7) |
| Urothelial carcinoma + mixed histology | 2 (7.4) |
| Pure squamous cell carcinoma | 2 (7.4) |
| Pure adenocarcinoma | 0 (0.0) |
| No malignancy | 5 (18.5) |
| Maximum tumour diameter (mm) | 30 (20–46) |
| Tumour location (%) | |
| Solitary | 16 (59.3) |
| Multilocular | 11 (40.7) |
| Number of tumour areas (%) | |
| 1 | 16 (59.3) |
| 2 | 10 (37.0) |
| 3 | 1 (3.7) |
| Location of tumour areas (%) | |
| Bladder dome | 10 (37.0) |
| Right side wall | 6 (22.2) |
| Left side wall | 7 (25.9) |
| Bladder ground | 3 (11.1) |
| Anterior wall | 1 (3.7) |
| Posterior wall | 6 (22.2) |
| Right ostium | 2 (7.4) |
| Left ostium | 2 (7.4) |
| Bladder neck | 1 (3.7) |
| Unknown | 1 (3.7) |
| Tumour stage TNM (UICC 2009) | |
| Pathological tumour stage T (%) | |
| pT0 | 5 (18.5) |
| pTa | 0 (0.0) |
| pT1 | 1 (3.7) |
| pT2 | 8 (29.6) |
| pT2a | 2 (7.4) |
| pT2b | 4 (14.8) |
| pT2X | 2 (7.4) |
| pT3 | 12 (44.4) |
| pT3a | 6 (22.2) |
| pT3b | 5 (18.5) |
| pT3X | 1 (3.7) |
| pT4 | 0 (0.0) |
| pTis (only) | 1 (3.7) |
| Presence of concomitant Carcinoma in situ (CIS) (%) | 3 (11.1) |
| Regional lymph node status N (%) | |
| pN0 | 19 (70.4) |
| pN1 | 4 (14.8) |
| pN2 | 2 (7.4) |
| pN3 | 0 (0.0) |
| pN+ | 6 (22.2) |
| pNX | 2 (7.4) |
| Number of positiv lymph nodes (metastasis) | 1.0 (1.0–3.0) |
| Distant metastasis M (%) | |
| M0 | 26 (96.3) |
| M1 | 1 (3.7) |
| MX | 0 (0.0) |
| Location of distant metastasis (%) | |
| Subcutaneous | 1 (3.7) |
| Grading (WHO 1973) (%) | |
| Grade 1 | 0 (0.0) |
| Grade 2 | 0 (0.0) |
| Grade 3 | 21 (77.8) |
| Unknown | 6 (22.2) |
| Grading (WHO 2004) (%) | |
| High-grade papillary urothelial carcinoma | 21 (77.8) |
| Low-grade papillary urothelial carcinoma | 0 (2.9) |
| Unknown | 6 (22.2) |
| Lymphovascular invasion (%) | |
| L0 | 21 (77.8) |
| L1 | 5 (18.5) |
| LX | 1 (3.7) |
| Vascular invasion (%) | |
| V0 | 19 (70.4) |
| V1 | 7 (25.9) |
| VX | 1 (3.7) |
| Surgical margins (%) | |
| R0 | 22 (81.5) |
| R1 | 4 (14.8) |
| R2 | 0 (0.0) |
| RX | 1 (3.7) |
| (D) | |
| Surgical characteristics | |
| Operative time (min) | 143.0 (114.0–220.0) |
| Pelvic lymph node dissection (%) | |
| Yes | 25 (92.6) |
| No | 2 (7.4) |
| Extent of pelvic lymph node dissection (%) | |
| Unilateral | 8 (29.6) |
| Bilateral | 17 (63.0) |
| Number of lymph nodes dissected | 10.0 (8.0–15.0) |
| Ureter reimplantation (%) | 9 (33.3) |
| Right side/left side | 6 (22.2)/3 (11.1) |
| Intraoperative ureter stenting (%) | 12 (44.4) |
| (E) | |
| Hospitalization course | |
| Hospitalization time (days) | 10.0 (10.0–15.0) |
| Intensive/Intermediate Care Unit rate (%) | 10.0 (37.0) |
| Intensive/Intermediate Care days | 1.0 (1.0–4.0) |
| Removal of bladder catheter (p.o. day) | 8.0 (7.0–10.0) |
| Removal of ureter stent (p.o. day) | 13.0 (10.0–32.0) |
Continuous data are shown as median with interquartile range (IQR). (PC) partial cystectomy, (m) male, (f) female, (ECOG) Eastern Cooperative Oncology Group, (UICC) Union Internationale Contre le Cancer, (MIBC) muscle-invasive bladder cancer, (p.o.) postoperative.